GNLX

#3925
Genelux Corporation Common Stock
2.64 USD
+4.35%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
2.64
2.64
Годовой диапазон
2.25
8.54
Дневное изменение
+4.35%
Месячное изменение
0.00%
6-месячное изменение
-50.00%
Годовое изменение
+5.18%
Предыдущее закрытие
2.53
Открыть
2.64
Bid
Ask
Минимум
2.64
High
2.64
Объем
9
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 118.29 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-5.07
Коэффициент цена/денежный поток
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Новости